{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:41:48Z","timestamp":1762094508421,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"publisher","award":["A14-195"],"award-info":[{"award-number":["A14-195"]}],"id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20fk0210065h0001"],"award-info":[{"award-number":["20fk0210065h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bbrc.2021.04.062","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T01:05:50Z","timestamp":1619658350000},"page":"78-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice"],"prefix":"10.1016","volume":"559","author":[{"given":"Kazuki","family":"Ohya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-2795","authenticated-orcid":false,"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Abe-Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-3544","authenticated-orcid":false,"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-2156","authenticated-orcid":false,"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-3268","authenticated-orcid":false,"given":"Chise","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HoJoong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Miyayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hijikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-5341","authenticated-orcid":false,"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.04.062_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus Resistance to Direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2021.04.062_bib3","article-title":"In\u00a0vitro antiviral activity and resistance profile of the next-generation HCV NS3-4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2021.04.062_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In\u00a0vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2021.04.062_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 Weeks in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbrc.2021.04.062_bib8","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2021.04.062_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2021.04.062_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","article-title":"Hiroshima Liver Study Group. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct acting antivirals therapy failures","volume":"54","author":"Osawa","year":"2019","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02217-17","article-title":"Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in HCV infected patients receiving glecaprevir and pibrentasvir in Japan","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2021.04.062_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142145","article-title":"Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice","volume":"10","author":"Tateno","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2021.04.062_bib13","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1099\/jgv.0.000726","article-title":"Usefulness of humanized cDNA-uPA\/SCID mice for the study of hepatitis B virus and hepatitis C virus virology","volume":"98","author":"Uchida","year":"2017","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1099\/jgv.0.001268","article-title":"Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice","volume":"100","author":"Osawa","year":"2019","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib15","doi-asserted-by":"crossref","first-page":"50301","DOI":"10.1074\/jbc.M305684200","article-title":"Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication","volume":"278","author":"Miyanari","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2021.04.062_bib16","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1099\/vir.0.83658-0","article-title":"Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice","volume":"89","author":"Kimura","year":"2008","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib17","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1128\/JVI.75.10.4614-4624.2001","article-title":"Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations","volume":"75","author":"Krieger","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1348-0421.2012.00437.x","article-title":"Replication and infectivity of a novel genotype 1b hepatitis C virus clone","volume":"56","author":"Date","year":"2012","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.bbrc.2021.04.062_bib19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/hepr.12882","article-title":"Reversi-type virologic failure\" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline","volume":"47","author":"Uchida","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2021.04.062_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbrc.2018.04.005","article-title":"Hiroshima Liver Study Group, Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice","volume":"500","author":"Teraoka","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2021.04.062_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165339","article-title":"Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure","volume":"11","author":"Itakura","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2021.04.062_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-0039-3402001","article-title":"NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors","volume":"40","author":"Hikita","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.bbrc.2021.04.062_bib23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"GS-US-342-1553 Investigators. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21006094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21006094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:39:38Z","timestamp":1762094378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21006094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":23,"alternative-id":["S0006291X21006094"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.04.062","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.04.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}